Opinion
Video
Author(s):
Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.
Frontline Palbociclib Opens the Door to Subsequent CDK4/6 Inhibition in Metastatic Breast Cancer
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Adjuvant Ribociclib Revamps HR+/HER2– Breast Cancer Management
Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
Ribociclib Earns Positive CHMP Opinion in HR+/HER2– Early Breast Cancer
T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress